Jean-Marie Cuillerot has been appointed Vice President and Global Head of Clinical Development at Agenus, Inc, Lexington, US, overseeing ongoing clinical development of checkpoint targeted antibodies, including AGEN1884 targeting CTLA-4 and INCAGN1876 targeting GITR. Dr. Cuillerot was Global Head of Clinical Development, Immuno-Oncology, and Vice President of Clinical Immunotherapy/ Immuno-Oncology at EMD Serono Research and Development Institute, an affiliate of Merck Serono, and prior to that at Bristol-Myers Squibb.
